By Tony Fong

NEW YORK (GenomeWeb News) – Nearly two weeks after an exclusivity period expired, Affymetrix remains in talks to acquire eBioscience, a company official said today.

Doug Farrell, vice president of investor relations for Affymetrix, told GenomeWeb Daily News that although the exclusivity period for Affy lapsed at the end of the day on March 31, neither firm has canceled the acquisition agreement announced in November, and they remain in ongoing discussions regarding a deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.